3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
4
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Precancerous Conditions
1
Neoplasms by Site
1
Neoplasms
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
Cisplatin
22
pembrolizumab
21
Carboplatin
12
Radiotherapy
11
Paclitaxel
11
Brachytherapy
11
Drug Therapy
10
Bevacizumab
9
Blood Specimen Collection
7
Colposcopy
6
Specimen Handling
5
Injections
5
toripalimab
4
Taxes
4
Surveys and Questionnaires
4
Nivolumab
4
Mass Screening
4
Human Papillomavirus DNA Tests
4
Gemcitabine
4
Chemotherapy, Adjuvant
4
Chemoradiotherapy
4
spartalizumab
3
lenvatinib
3
camrelizumab
3
aldesleukin
3
Restraint, Physical
3
Radiation
3
Fulvestrant
3
Cyclophosphamide
3
Biopsy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Uterine Cervical Neoplasms
×
Acetic Acid
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled